

41. Mokaddas E, Khan ZU, Ahmad S, Nampoory MR, Burhamah M. (2011) Value of (1→3)-β-d-glucan, *Candida* mannan and *Candida* DNA detection in the diagnosis of candidaemia. Clin. Micro. Infect. 17: 1549-53.
42. Montagna MT, Coretti C, Lovero G, De Giglio O, Montagna O, Laforgia N, Santoro N, Caggiano G. (2011) Diagnostic performance of (1→3)-β-d-glucan in neonatal and pediatric patients with candidemia. Int. J. Mol. Sci. 2011;12(9): 5871-7.
43. Mularoni, A., Furfaro, E., Faraci, M., Franceschi, A., Mezzano, P., Bandettini, R., Viscoli, C., and Castagnola, E. (2010) High Levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease. Clin. Vaccine Immunol. 17: 882-3.
44. Obayashi, T., Negishi, K., Suzuki, T., and Funata, N. (2008) Reappraisal of the serum (1→3)-beta-D-glucan assay for the diagnosis of invasive fungal infections—a study based on autopsy cases from 6 years. Clin. Infect. Dis. 46: 1864-1870.
45. Odabasi, Z., Mattiuzzi, G., Estey, E., Kantarjian, H., Saeki, F., Ridge, R., Ketchum, P., Finkelman, M., Rex, J. and Ostrosky-Zeichner, L. (2004) Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Clinical Infectious Diseases. 39: 199-205.
46. Odabasi, Z., Paetznick, V.L., Rodriguez, J.R., Chen, E., McGinnis, M.R., and Ostrosky-Zeichner, L. (2006) Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med. Mycol. 44: 267-72.
47. Ostrosky-Zeichner, L., Alexander, B.D., Kett, D.H., Vazquez, J., Pappas, P.G., Saeki, F., Ketchum, P.A., Wingard, J., Schiff, R., Tamura, H., Finkelman, M.A., and Rex, J.H. (2005) Multicenter clinical evaluation of the (1→3)-β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin. Inf. Dis. 41: 299-305.
48. Ostrosky-Zeichner, L., Paetznick, V.L., Rodriguez, J., Chen, E., and Sheehan, D.J. (2009) Activity of anidulafungin in a murine model of *Candida krusei* infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1→3)-β-D-glucan levels. Antimicrob. Agents Chemother. 53: 1639-1641.
49. Pazos, C., Ponton, J., and Del Palacio, A. (2005) Contribution of (1→3)-β-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: A comparison with serial screening for circulating galactomannan. Journal of Clinical Microbiology 43(1): 299-305
50. Pazos, C., Moragues, M-D., Quindos, G., and del Palacio, A. (2006) Diagnostic potential of (1→3)-β-D-glucan and anti-*Candida albicans* germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev. Iberoam Micol. 23: 209-215
51. Persat, F., Ranque, S., Derouin, F., Michel-Nguyen, A., Picot, S., and Sulahian, A. (2008) Contribution of the (1→3)-β-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections. J. Clin. Micro. 36: 1009-1013.
52. Petraitiene, R., Petraitis, V., Hope, W.W., Mickiene, D., Kelaher, A.M., Murray, H.A., Mya-San, C., Hughes, J.E., Cotton, M.P., Bacher, J., and Walsh, T.J. (2008) CSF and Plasma (1→3)-β-D-glucan as surrogate markers for detection and therapeutic response of experimental hematogenous candida meningoenephalitis. Antimicrobial Agents and Chemotherapy Antimicrob. Agents. Chemo. 52: 4121-4129.
53. Pickering, J.W., Sant, H.W., Bowles, C.A., Roberts, W.L., and Woods, G.L. (2005) Evaluation of a (1→3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J. Clin. Micro. 43: 5957-62.
54. Ponton, J. (2009) Usefulness of biological markers in the diagnosis of invasive candidiasis. Rev. Iberoam. Micol. 26: 8-14.
55. Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, Maviglia R, Fadda G, Sanguinetti M, Antonelli M. (2011) Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, *Candida* Score, and colonization index. Crit Care. 22;15(5): R249. [Epub ahead of print]
56. Sax, P.E. and Piscuilli, M.L. (2008), Use of a serum β-D-glucan assay for diagnosis of HIV-related *Pneumocystis jiroveci* pneumonia in patients with negative microscopic examination results. CID 46: 1928-1930.
57. Sax, P.E., Komarow, L., Finkelman, M., Grant, P.M., Andersen, J., Scully, E., Powderly, W.G., and Zolopa, A.R. for the AIDS Clinical Trials Group Study A5164 Team. Blood (1→3)-β-D-Glucan as a diagnostic test for HIV-related *Pneumocystis jirovecii* pneumonia. Clin. Inf. Dis. 2011;53: 197-202.
58. Shupp JW, Petraitiene R, Jaskille AD, Pavlovich AR, Matt SE, Nguyen DT, Kath MA, Jeng JC, Jordan MH, Finkelman M, Walsh TJ, Shoham S. (2011) Early serum (1→3)-β-D-glucan levels in patients with burn injury. Mycoses. 2011 Jul 19. doi: 10.1111/j.1439-0507.2011.02068.x. [Epub ahead of print]
59. Smith, P.B., Benjamin, D.K., Alexander, B.D., Johnson, M.D., Finkelman, M.A., and Steinbach, W.J. (2007) (1→3)-β-D-Glucan levels in pediatric patients: Preliminary data for the use of the beta-glucan test in children. Clin. Vaccine Immunol. 14: 924-925.
60. Racil, Z., Kocmanova, I., Lengerova, M., Weinbergerova, B., Buresova, L., Toskova, M., Winterova, J., Timilsina, S., Rodriguez, I., Mayer, J. (2010) Difficulties in using 1,3-beta-D glucan as the screening test for the early diagnosis of invasive fungal diseases in patients with hematological malignancies - high frequency of false positive results and their analysis. J. Med. Micro. 59: 1016-1022.
61. Rafailidis, P. I., Falagas, M.E., Khan, Z.U., Ahmad, S., Mokaddas, E., Said, T., Nair, M.P., Halim, M.A., Nampoory, M.R., and McGinnis, M.R. (2007) Cerebral aspergillosis diagnosed by detection of *Aspergillus flavus*-specific DNA, galactomannan and (1→3)-beta-D-glucan in clinical specimens. J. Med. Micro. 56: 129-32.
62. Thornton, C.R. (2008) Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin. Vaccine Immunol. 2008 15:1095-105.
63. Wiederhold, N.P., Najjar, L.K., Vallor, A.C., Kirkpatrick, W.R., Bocanegra, R., Molian, D., Olivo, M., Graybill, J.R., and Patterson, T.F. (2008) Assessment of (1→3)-β-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis Antimicrob. Agents and Chemotherapy. Antimicrob. Agents Chemother. 52: 1176-1178.

Resource Links

Dr. Fungus - www.doctorfungus.org

Aspergillus Website - www.aspergillus.man.ac.uk

Associates of Cape Cod, Inc. - www.acciusa.com/clinical/

PubMed - www.ncbi.nlm.nih.gov/entrez/query.fcgi

Fungitell® Assay

(1→3)-β-D-Glucan Reference List



Associates of Cape Cod, Inc. and Beacon Diagnostics® Laboratory are not responsible or liable for the content of external resource links. Only the operators of the linked pages are responsible for their content.

Reference List

1. Acosta, J., Catalan, M., Del Palacio-Peréz-Medel, A., Lora, D., Montejo, J.C., Cuetara, M.S., Moragues, M.D., Ponton, J., Del Palacio, A. (2010). A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1→3)-β-D-glucan chromogenic assay in serum samples. *Clin. Micro. Infect.* Article first published online: 17: 1053-1060.
2. Acosta J, Catalan M, Del Palacio-Pérez-Medel A, Montejo JC, De-La-Cruz-Bértolo J, Moragues MD, Pontón J, Finkelman MA, Del Palacio A. (2011) Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-β-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease. *Eur J. Clin. Microbiol Infect Dis.* 2011 Aug 3. [Epub ahead of print]
3. Ahmad, S., Khan, Z.U., and Theyyathel, A.M. (2007) Diagnostic value of DNA, (1→3)-β-D-glucan, and galactomannan detection in serum and bronchoalveolar lavage of mice experimentally infected with *Aspergillus terreus*. *Diagn. Micro. Infect. Dis.* 59: 165-71
4. Alexander, B.D., Smith, P.B., Davis, R.D., Perfect, J.R., Reller, L.B.. (2010). The (1,3)-beta-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. *J. Clin. Micro.* 48: 4083-8.
5. Bellanger AP, Grenouillet F, Henon T, Skana F, Legrand F, Deconinck E, Millon L. (2011) Retrospective assessment of β-D-(1,3)-glucan for presumptive diagnosis of fungal infections. *APMIS.* 4-5: 280-286.
6. Chowdhary A, Randhawa HS, Singh V, Khan ZU, Ahmad S, Kathuria S, Roy P, Khanna G, Chandra J. (2011) *Bipolaris hawaiiensis* as etiologic agent of allergic bronchopulmonary mycosis: first case in a paediatric patient. *Med. Mycol.* 49: 760-5.
7. Cuetara, M. S., Alhambra, A., Moragues, M.D., Gonzalez-Elorza, E., Ponton, J., and Del Palacio, A. (2009) Detection of (1→3)-β-D-glucan as an adjunct to diagnosis in a mixed population with uncommon proven fungal diseases or unusual clinical presentation. *Clin. Vacc. Immunol.* 16: 423-426.
8. De Vlieger G, Lagrou K, Maertens J, Verbeken E, Meersseman W, Van Wijngaerden E. (2011) Beta-D-glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised critically ill patients with symptoms of respiratory infection: an autopsy-based study. *J. Clin. Micro.* 49: 3783-7.
9. Del Bono, V., Mularoni, A., Furfaro, E., Delfino, E., Rosasco, L., Miletich, F., and Viscoli, C. (2009) clinical evaluation of (1→3)-β-D-Glucan assay in presumptive *Pneumocystis jirovecii* pneumonia in immunocompromised patients. *Clin. Vacc. Immunol.* 16: 1524-1526.
10. Del Bono V, Delfino E, Furfaro E, Mikulska M, Nicco E, Bruzzi P, Mularoni A, Bassetti M, Viscoli C. Clinical Performance of the (1,3)-β-D-Glucan Assay in Early Diagnosis of Nosocomial *Candida* Bloodstream Infections. (2011) *Clin. Vaccine Immunol.* 2011 Dec;18(12): 2113-7.
11. Del Palacio, A., Llenas-García, J., Soledad Cuétara, M., Pulido, F., Rubio, R., Pontón, J., Del Palacio-Pérez-Medel, A. (2010) Serum (1→3)-beta-D-Glucan as a noninvasive adjunct marker for the diagnosis and follow-up of *Pneumocystis jirovecii* pneumonia in patients with HIV infection. *Clin. Infect. Dis.* 50: 451-2.
12. Desmet, S., Van Wijngaerden, E., Maertens, J., Verhaegen, J., Verbeken, E., De Munter, P., Meersseman, W., Van Meensel, B., Van Eldere, J., Lagrou, K., (2009) Serum (1-3)-beta-D-glucan as a tool for diagnosis of *Pneumocystis jirovecii* pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. *J. Clin. Micro.* 47: 3871-4
13. Digby, J., Kalbfleisch, J., Glenn, A., Larsen, A., Browder, W., and Williams, D. (2003) Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. *Clin. Diagn. Laboratory. Immunol.* 10: 802-805.
14. Duffner, U., Abdel-Mageed, A., Dahl, K., Fogg, G., and Hester, J. (2011) Serum (1→3)-β-D-glucan levels (Fungitell assay) is not useful as a screening test for recipients of an allogeneic HSCT while on immunoglobulin replacement. *Bone Marrow Transpl.* 47: 151-152
15. Egan, L., Connolly, P., Wheat, L. J., Fuller, D., Davis, T. E., Knox, K. S. and Hage, C. A. (2007) Histoplasmosis as a cause for a positive Fungitell™ (1→3)-β-D-glucan test, *Medical Mycology*, 46: 93-95.
16. Eggimann P, Marchetti O (2011) Is (1→3)-β-D-glucan the missing link from bedside assessment to pre-emptive therapy of invasive candidiasis? *Crit Care.* 15: 1017. [Epub ahead of print]
17. Ellis, M., Ramadi, B., Finkelman, M., Hedstrom, U., Kristenson, J., Ali-Zadeh, H., and Klingspor, L. (2007) Assessment of the clinical utility of serial β-D-glucan concentrations in patients with persistent neutropenic fever. *J. Med. Micro.* 57: 287-95.
18. Finkelman, M.A., (2010) *Pneumocystis jirovecii* infection: Cell wall (1→3)-β-D-glucan: Biology and diagnostic utility. *Crit. Rev. Micro.* 36: 271-81.
19. Finkelman, M.A. and Tamura, H. (2005) Detection and measurement of (1→3)-beta-D-glucan. In "Toxicology of (1→3)-Beta-Glucans," Young, S.H. and Castranova, V, eds. CRC Press, New York.
20. Girouard, G., Lachance, C., Pelletier, R. (2007) Observations on (1→3)-beta-D-glucan detection as a diagnostic tool in endemic mycosis caused by *Histoplasma* or *Blastomyces*. *J. Med. Micro.* 56: 1001-2
21. Gonzales, B.E., Faverio, L.A., Marty, F.M., MacArthur, C., and Churchill, R.B. (2011) Elevated serum beta-D-glucan levels in immunocompromised children with clinical suspicion for *Pneumocystis jirovecii* pneumonia. *Clin. Vacc. Immunol.* 18: 2043-2049.
22. Hachem, R.Y., Kontoyiannis, D.P., Chemaly, R.F., Jiang, Y., Reitzel, R., and Raad, I. (2008) Utility of galactomannan enzyme immunoassay and (1→3)-beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for *Aspergillus fumigatus* infection in hematologic malignancy patients. *J. Clin. Micro.* 47: 129-133.
23. Hale, T.W., Bateman, T.L., Finkelman, M.A., and Berens, P.D. (2009) The absence of *Candida albicans* in milk samples of women with symptoms of ductal candidiasis (2009) *Breastfeeding Med.* 4: 57-61.
24. Held, J., Koch, M., Reischl, U., Danner, T., Serr, A. (2011) Serum (1→3)-beta-D-Glucan measurement as early indicator for *Pneumocystis jirovecii* pneumonia and evaluation of its prognostic value. *Clin. Micro. Infect.* 17: 595-602.
25. Held, J. and Wagner, D. (2011) β-D-Glucan kinetics for the assessment of treatment response in *Pneumocystis jirovecii* pneumonia. *Clin. Micro. Infect.* 17: 1118-1122
26. Heyland, D., Jiang, X., Day, A.G., and Laverdiere, M. (2011) Serum β-d-glucan of critically ill patients with suspected ventilator-associated pneumonia Preliminary observations. *J. Crit. Care.* In Press.
27. Issa NC, Koo S, Lynch RC, Gay C, Hammond SP, Baden LR, Ghobrial IM, Finkelman MA, Marty FM. (2011) Serum galactomannan and (1→3)-β-D-glucan assays in patients with Multiple Myeloma and Waldenström's Macroglobulinemia. *J. Clin. Micro.* 2011 Dec 14. [Epub ahead of print]
28. Karageorgopoulos, D.E., Vouloumanou, E.V., Ntziora, F., Michalopoulos, A. β-D-Glucan assay for the diagnosis of invasive fungal infections: A meta-analysis. *Clin. Inf. Dis.* 2011; 52: 750-770.
29. Koo, S., Bryar, J.M., Page, J.H., Baden, L.R., and Marty, F.M. (2009) Diagnostic performance of the (1→3)-beta-D-glucan assay for invasive fungal disease. *Clin. Infect. Dis.* 49:1650-9.
30. Kondori, N., Edebo, L., and Mattsby-Baltzer, I. (2004) Circulating (1→3)-β-D-glucan and Immunoglobulin G subclass antibodies to *Candida albicans* cell wall antigens in patients with systemic candidiasis. *Clinical and diagnostic Laboratory Immunology.* 11(2): 344-350
31. Mackay CA, Ballot DE, Perovic O. (2011) Serum 1,3-β-D-Glucan assay in the diagnosis of invasive fungal disease in neonates. *Pediatr Rep.* 2011 Jun 16;3(2):e14.
32. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S. (2011) ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. *Bone Marrow Transplant.* 2011 Sep 19. doi: 10.1038/bmt.2011.178. [Epub ahead of print]
33. Marty, F.M., Lowry, C.M., Lempitski, S.J., Kubiak, D.W., Finkelman, M.A., and Baden, L. R., (2006) Reactivity of (1→3)-β-D-Glucan assay with commonly used intravenous antimicrobials. *Antimicrob. Agents Chemo.* 50: 3450-3453.
34. Marty, F. M., Koo, S., Bryar, J., and Baden, L.R. (2007) (1→3)-β-D-glucan assay positivity in patients with *Pneumocystis (carinii) jirovecii* pneumonia. *Ann. Int. Med.* 147: 70-72.
35. Marty, F. M. and Koo, S. (2008) Role of (1→3)-β-D-Glucan in the diagnosis of invasive aspergillosis. *Medical Mycology* 47: Suppl. 1: S233-240.
36. Mennink-Kersten, M.A., Rugebrink, D., Wasei, N., Melchers, W.J., and Verweij, P.E. (2006) In vitro release by *Aspergillus fumigatus* of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. *J. Clin. Micro.* 44: 1711-8.
37. Metan, G., A ku, C., Buldu, H., Koç, A.N. (2010). The interaction between piperacillin/tazobactam and assays for *Aspergillus* galactomannan and 1,3-beta-D-glucan in patients without risk factors for invasive fungal infections *Infection.* 38: 217-21.
38. Metan G, Agkuc C, Nedret Koc A, Elmali F, Finkelman MA. (2011) Does ampicillin-sulbactam cause false positivity of (1,3)-beta-D-glucan assay? A prospective evaluation of 15 patients without invasive fungal infections *Mycoses.* 2011 Nov 1. doi: 10.1111/j.1439-0507.2011.02131.x. [Epub ahead of print]
39. Mikulska, M., Furfaro, E., Del Bono, V., Gualandi, F., Van Lint, M.T., Miletich, F., Bacigalupo, A., and Viscoli, C. (2011) Persistence of positive (1,3)-beta-glucan test after clearance of candidemia in HSCT recipients. *Clin. Vacc. Immunol.* 18: 518-519.
40. Mohr, J.F., Sims, C., Paetznick, V., Rodriguez, J., Finkelman, M.A., Rex, J.H., and Ostrosky-Zeichner, L. (2011). A Prospective survey of (1→3)-β-D-glucan and its relationship to Invasive candidiasis in the surgical ICU setting. *J. Clin. Micro.* 49: 58-61.